APT-1011

a fluticasone propionate orally disintegrating tablet formulation

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Eosinophilic Esophagitis 01/01/2020 - "APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate under development for the treatment of eosinophilic esophagitis. "
2.	Eosinophilia 01/01/2020 - "To evaluate the safety and tolerability of APT-1011 administered to patients with EoE and to assess the effect on clinical symptoms of EoE, endoscopic appearance and oesophageal eosinophilia. "
3.	Deglutition Disorders (Dysphagia) 11/01/2022 - "APT-1011 dosing regimens were superior for histologic and endoscopic responses, and for reduction in dysphagia frequency vs placebo. "
4.	Candidiasis (Moniliasis) 11/01/2022 - "APT-1011 was safe and well-tolerated, with higher incidence of candidiasis noted at the higher twice daily doses. "
5.	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/01/2020 - "In one participant randomised to 1.5 mg APT-1011 BID, a reduction in cortisol was observed, but without evidence of adrenal insufficiency. "